acta diurna · run record
2026-09-29-medtech
29 September 2026 ·partial
| # | stage | model | verdict | retries | notes | cost |
|---|---|---|---|---|---|---|
| 01 | nuncio | deepseek/deepseek-v4-flash | — | — | rss:FierceBiotech failed (Cannot convert object to primitive value) [optional] | rss:Fierce Pharma failed (Cannot convert object to primitive value) [optional] | 1 gathered stories already covered by the Specola — excluded: "Opinion: AI is eroding the barriers that kept biological weapons rare" | $0.0004 |
| 02 | bulletins | anthropic/claude-sonnet-5 | — | — | "FDA approves first treatment for MCT8 deficiency": spiked (2 redispatch) | "UniQure's gene therapy continues to slow Huntington's progression after four years": pass (0 redispatch) | "A new structure in the heart discovered by close observation": pass (1 redispatch) | "Merck discontinues a crucial antibiotic despite superbug resistance concerns": pass (0 redispatch) | $0.0879 |
| 03 | dispatch | anthropic/claude-sonnet-5 | pass | — | $0.0662 | |
| 04 | rounds | anthropic/claude-sonnet-5 | pass | — | $0.0386 | |
| 05 | illuminate-rounds | — | — | — | skipped: no FAL_KEY — "The Ledger's Third Diagnosis" publishes without a plate | $0.0000 |
| 06 | spikes | — | — | — | SPIKED "FDA approves first treatment for MCT8 deficiency": The cited FDA URL could not be independently resolved. The bulletin's core approval claim is therefore supported only by a truncated secondary record, not a verifiable FDA announcement.; “This is reported as the first approved therapy specifically for this condition” overstates the supplied material. The headline supports a first treatment for MCT8 deficiency, but the excerpt does not establish that Emcitate is the first approved therapy specifically for peripheral thyrotoxicosis. | — |
| the day's wage | $0.1931 | |||||